<DOC>
	<DOCNO>NCT00002673</DOCNO>
	<brief_summary>RATIONALE : White blood cell donor expose cytomegalovirus may able help prevent infection occur patient undergo bone marrow peripheral stem cell transplantation . PURPOSE : Phase II trial study effectiveness donate white blood cell prevent cytomegalovirus infection patient undergo bone marrow peripheral stem cell transplantation .</brief_summary>
	<brief_title>Immunotherapy Treating Patients Who Are Undergoing Bone Marrow Peripheral Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether adoptive immunotherapy comprise donor-derived CD8+ , CMV-specific , major histocompatibility complex class I-restricted cytotoxic T-lymphocyte ( CTL ) clone ( CD8+ CMV-specific CTL clone ) CD4+ CMV-specific T-helper ( Th ) -cell clone effective prevent CMV viremia disease CMV-positive patient malignancy require allogeneic bone marrow peripheral blood stem cell transplantation . II . Determine whether transfer CD4+ CMV-specific Th-cell clone patient deficient response reconstitute CD4+ Th-cell activity augment adoptively transfer CD8+ CMV-specific CTL clone . OUTLINE : Allogeneic CD8+ CMV-specific , major histocompatibility complex class I-restricted cytotoxic T-lymphocyte ( CTL ) clone ( CD8+ CMV-specific CTL clone ) CD4+ CMV-specific T-helper ( Th ) -cell clone harvest cultured vitro least 2 week bone marrow peripheral blood stem cell ( PBSC ) transplantation . Bone marrow PBSC infuse day 0 . Patients receive first infusion CD8+ CMV-specific CTL clone begin day 28 45 posttransplantation , follow 8 day later second infusion , follow 2 day later first infusion CD4+ CMV-specific Th-cell clone . Patients receive prednisone posttransplantation deficient CD8+ CTL response ( i.e. , less 50 % response measure immunocompetent bone marrow donor ) second infusion CD8+ CMV-specific CTL clone receive third infusion CD8+ CMV-specific CTL clone second infusion CD4+ CMV-specific Th-cell clone day 67 . PROJECTED ACCRUAL : A total 30 patient accrue study within 12-18 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : See General Eligibility Criteria PATIENT CHARACTERISTICS : See General Eligibility Criteria PRIOR CONCURRENT THERAPY : See Disease Characteristics Patients Characteristics Age : 12 60 Performance status : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>testicular embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma</keyword>
	<keyword>testicular teratoma</keyword>
	<keyword>testicular yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma teratoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor seminoma</keyword>
	<keyword>testicular embryonal carcinoma seminoma</keyword>
	<keyword>testicular yolk sac tumor teratoma</keyword>
	<keyword>testicular yolk sac tumor teratoma seminoma</keyword>
	<keyword>testicular choriocarcinoma yolk sac tumor</keyword>
	<keyword>testicular choriocarcinoma embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma teratoma</keyword>
	<keyword>testicular choriocarcinoma seminoma</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>ovarian yolk sac tumor</keyword>
	<keyword>ovarian embryonal carcinoma</keyword>
	<keyword>ovarian polyembryoma</keyword>
	<keyword>ovarian choriocarcinoma</keyword>
	<keyword>ovarian teratoma</keyword>
	<keyword>ovarian immature teratoma</keyword>
	<keyword>ovarian mature teratoma</keyword>
	<keyword>ovarian monodermal highly specialized teratoma</keyword>
	<keyword>stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage II adult Burkitt lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>infection</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>